This gallery contains 1 photo.
March 2021. Several terms and acronyms are used to describe the levonorgestrel-releasing intrauterine device: ‘LNG-IUD’, ‘Hormonal-IUD’, and ‘LNG-IUS’. The use…
February 2021. The Radio Télévision Suisse program 15 Minutes, looks at the Swiss model of emergency contraception dispensation through pharmacies, in which consultation is mandatory and paid for by the client.
Journalist Coraline Pauchard looks at the pros and cons of this model, in a report that you can listen here (in French).
February 2021. The World Health Organization just added two chapters to its Family Planning Handbook. One of them addresses contraception delivery during an epidemic.
These are some of the recommendations:
Overarching messages of this chapter are:
January, 2021. Scientists at University of Utah Health found that hormonal intra uterine devices (IUDs) were comparable to copper IUDs for use as emergency contraceptives. According to the researchers, the finding supports adding hormonal IUDs to current emergency contraception options. Read more here.
January 2021. The European Consortium for Emergency Contraception (ECEC) and the European Youth Network on Sexual and Reproductive Rights (YouAct), launched in 2019 a participatory survey in order to better understand how access to and availability of emergency contraception (EC) pills is through community pharmacies in our region.
We are pleased to introduce the survey report, which focuses on five countries: Andorra, Bosnia and Herzegovina, Malta, Spain and Sweden. You can download the report here.
Our findings suggest that community pharmacies play a very important role in ensuring access to EC pills, with the big majority of pharmacies carrying them (even in countries where they are entitled not to). However, our findings also point at individuals not being systematically offered a choice of postcoital contraception methods in every pharmacy of our sample.
We conclude that access to the highest standard of care in post-coital contraception remains uneven within and among countries in Europe: individuals are likely to have different experiences and outcomes when procuring EC, depending on what European country she/he is in, and also on what pharmacy she/he walks in.
ECEC and YouAct recommend some measures to reduce inequities in access to the highest standard of post-coital contraception care. These include:
Different responsibilities fall on different players. We look forward to starting a conversation to move forward toward a stronger rights-based approach to EC dispensing.
We thank all the organizations, individuals and pharmacy staff that participated in this effort.
Contact us at ecec[at]eeirh[dot]org and join our e-mail list.
January 2021. New brands of ulipristal acetate emergency contraception pills are becoming available in some European countries; as of January 2021 these can be found in Austria, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Poland, Portugal, Romania and Spain. Visit the Country by country section of our website for more details on specific brands available in each country.
January 2021. The American Society for Emergency Contraception just published EC for Transgender and Nonbinary Patients. This fact sheet is a great resource for all healthcare providers offering care to patients of reproductive age.
“Pregnancy is possible for any individual with a uterus and ovary(ies) who has receptive penis-in-vagina sex with partners who produce sperm, regardless of gender identity. Patients who are amenorrheic due to testosterone use may (…) be at risk for pregnancy. This fact sheet addresses medical and social-emotional aspects of EC for transgender and nonbinary patients.
December 2020. In Malta, a discussion is being held in Parliament these days, about the need for all pharmacies in the country to carry emergency contraception (EC) pills, in order to ensure timely access to this contraceptive method.
Surprisingly, some members of parliament still consider that EC pills can threaten Maltese law, under which human life is protected from conception.
We thought it would not be necessary to say it one more time (we are almost in 2021), but we will do this again: EC pills work mainly by preventing or delaying ovulation; if ovulation cannot be stopped and fertilisation occurs, EC pills will not interfere with implantation.
If you are going to design a reproductive health public policy, and think you should learn more about EC before, we kindly advice you to read:
December 2020. On November 26, the Members of the European Parliament adopted a resolution condemning the setback to women’s sexual and reproductive rights in Poland, and drawing attention to the legal obligation of the European Union to uphold and protect these rights. The resolution also urges Polish authorities to repeal the law limiting access to the emergency contraceptive pill.
In 2015, UPA EC pills became directly available from pharmacies in Poland (and in all European Union countries except for Hungary) as a result of European Medicines Agency’ recommendations. However, in July 2017, a new law entered into effect in Poland, reinstating mandatory prescription for UPA EC. Local experts report that doctors often deny prescriptions for EC pills on the grounds of personal beliefs.
Poland and Hungary are the sole European Union countries that still require a prescription for EC pills. Both countries disregard EC pills safety profile, and the fact that time to treatment is essential to maximize efficacy.
Read “European Parliament resolution of 26 November 2020 on the de facto ban on the right to abortion in Poland (2020/2876(RSP))” here.
November 2020. The Spanish Society for Contraception (SEC) just published the findings of its annual National Contraception Survey 2020, based on phone interviews conducted among 1800 women of reproductive age, between July and August 2020.
With regards to emergency contraception (EC) use, 38% of the women surveyed reported having ever used EC at some point of their lives. The percentage exceeds 40% among women between ages of 20 to 39. In previous surveys conducted by SEC in 2018 and 2011, 30% and 14% of the respondents, respectively, reported having ever used EC.
This shows a clear trend of increased use since prescription requirements were removed in 2009. This trend has also been observed in other European countries such as Italy (see Ministry of Health report of 2018). To our knowledge, only Norway has registered a decrease in EC use in the past few years. According to local experts, this is likely due to efforts to make ongoing contraception more accessible, and to a strong uptake of long acting reversible contraception methods (LARCs) among younger women.